Publications by authors named "Peter Belesiotis"

Background: Given that peripheral arterial disease (PAD) disproportionately affects people of lower socioeconomic status, out-of-pocket expenses for preventive medications are a major barrier to their use. We carried out a cost comparison of drug therapies for PAD to identify prescribing strategies that minimize out-of-pocket expenses for these medications.

Methods: Between March and June 2019, we contacted outpatient pharmacies in Hamilton, Ontario, Canada, to assess pricing of pharmacologic therapies at dosages included in the 2016 American College of Cardiology/American Heart Association guideline for management of lower extremity PAD.

View Article and Find Full Text PDF

Background: Postoperative atrial fibrillation (POAF) is the most common complication after cardiac surgery; it is associated with morbidity and mortality. We undertook this review to compare the effects of rhythm vs. rate control in this population.

View Article and Find Full Text PDF
Article Synopsis
  • Genome sequencing (GS) is being explored as a thorough prenatal diagnostic tool for detecting fetal abnormalities, alongside current standard methods like exome sequencing and microarray testing.
  • In a study involving 37 fetuses with structural issues identified through ultrasound, GS found diagnostic variants in 14% of cases and variants of uncertain significance in 19%.
  • The results suggest that GS could streamline the diagnostic process by potentially replacing several tests, providing faster and more comprehensive results for prenatal diagnosis.
View Article and Find Full Text PDF

Introduction: Daily medication is the cornerstone of evidence-based therapy to reduce mortality and morbidity in patients with heart failure (HF). Up to 20% of Canadian patients pay for medications out of pocket. We sought to identify strategies that patients and prescribers can employ to reduce these costs.

View Article and Find Full Text PDF

Background: Starting in the late 1990s, the pharmaceutical industry sought to increase prescribing of opioids for chronic non-cancer pain. Influencing the content of clinical practice guidelines may have been one strategy industry employed. In this study we assessed potential risk of bias from financial conflicts of interest with the pharmaceutical industry in guidelines for opioid prescribing for chronic non-cancer pain published between 2007 and 2013, the peak of opioid prescribing.

View Article and Find Full Text PDF